It has been demonstrated that PD-L1 promotes EMT in esophageal cancer, pancreatic cancer, breast cancer, and non-small cell lung cancers, leading to tumor progression [13–16]. This evidence concerns the gene CD274 and familial pancreatic carcinoma.